Johnson & Johnson (NYSE: JNJ) is an elite income investment because of its Dividend King status, healthy balance sheet, and incredibly strong, defensive business model. Critical details include its product portfolio and pipeline, which are producing numerous catalysts simultaneously in 2026.
A wave of approvals, expanded uses, and pipeline advances promises sustained growth, robust cash flow, and capital return safety long into the future. Which is why the mid-July price pullback, triggered by the earnings results and guidance, is a textbook entry point.
